People: ARIAD Pharmaceuticals Inc (ARIA.O)

ARIA.O on Nasdaq

6.08USD
2:27pm EDT
Price Change (% chg)

$0.10 (+1.67%)
Prev Close
$5.98
Open
$6.09
Day's High
$6.25
Day's Low
$6.02
Volume
6,147,237
Avg. Vol
8,139,300
52-wk High
$23.00
52-wk Low
$2.15

Search Stocks

Summary

Name Age Since Current Position

Harvey Berger

64 2004 Chairman of the Board, President, Chief Executive Officer

Edward Fitzgerald

59 2010 Chief Financial Officer, Executive Vice President, Treasurer

Martin Duvall

52 2013 Executive Vice President, Chief Commercial Officer

David Berstein

62 2013 Senior Vice President, General Counsel and Chief Intellectual Property Counsel, and Secretary

Maria Cantor

46 2013 Senior Vice President - Corporate Affairs and Human Resources

Daniel Bollag

53 2009 Senior Vice President - Regulatory Affairs and Quality

Hugh Cole

49 2014 Senior Vice President, Chief Business Officer

Frank Haluska

55 2012 Senior Vice President - Clinical Research and Development and Chief Medical Officer

Timothy Clackson

49 2010 President - Research and Development, Chief Scientific Officer

Wayne Wilson

65 2014 Lead Independent Director

Athanase Lavidas

66 2014 Director

Sarah Schlesinger

54 2013 Director

Alexander Denner

44 2014 Independent Director

Jay LaMarche

67 2000 Independent Director

Massimo Radaelli

56 2008 Independent Director

Norbert Riedel

56 2011 Independent Director

Robert Whelan

62 2010 Independent Director

Kendra Adams

Director - Investor Relations

Biographies

Name Description

Harvey Berger

Dr. Harvey J. Berger, M.D., is Chairman of the Board, President, Chief Executive Officer of Ariad Pharmaceuticals, Inc. He is principal founder and has served as Chairman of the Board and Chief Executive Officer since April 1991. He served as President from April 1991 to September 2003 and from December 2004 to present. He is chair of the Executive Committee. From 1986 to 1991, Dr. Berger held a series of executive management positions at Centocor, Inc., a biotechnology company, including Executive Vice President and President, Research and Development Division. He has also held senior academic and administrative appointments at Emory University, Yale University and the University of Pennsylvania and was an Established Investigator of the American Heart Association. Dr. Berger currently serves as a member of the Dean’s Council of Yale School of Medicine. Dr. Berger received his A.B. degree in Biology from Colgate University and his M.D. degree from Yale University School of Medicine. He obtained further medical and research training at the Massachusetts General Hospital and Yale-New Haven Hospital.

Edward Fitzgerald

Mr. Edward M. Fitzgerald is Chief Financial Officer, Executive Vice President, Treasurer of Ariad Pharmaceuticals, Inc. since June 2010. Previously, he served as Senior Vice President, Chief Financial Officer and Treasurer from May 2002 to June 2010. Mr. Fitzgerald received his B.S. degree in accounting and M.B.A. degree in finance from Babson College.

Martin Duvall

Mr. Martin J. Duvall is Executive Vice President, Chief Commercial Officer of Ariad Pharmaceuticals, Inc. He has served as company's Executive Vice President, Chief Commercial Officer since December 2013, having served as company's Senior Vice President, Commercial Operations since September 2011. Previously, from 2010 to 2011, he served as Senior Vice President and General Manager of Merck and Company’s global oncology franchise. From 2009 to 2010, Mr. Duvall led global marketing and commercial operations at Abraxis Bioscience, Inc. From 2004 to 2009, Mr. Duvall held roles leading commercial operations, commercial development and oncology strategy for MGI Pharma, Inc. and its acquirer, Eisai Pharmaceuticals.

David Berstein

Mr. David L. Berstein, Esq., is Senior Vice President, General Counsel and Chief Intellectual Property Counsel, and Secretary of Ariad Pharmaceuticals, Inc. He has served as company's Senior Vice President, General Counsel and Chief Intellectual Property Officer and Secretary since November 2013, having served as company's Senior Vice President and Chief Intellectual Property Officer since May 2008. Previously, he served as company's Senior Vice President and Chief Patent Counsel from June 2003 to June 2007.

Maria Cantor

Ms. Maria E. Cantor is Senior Vice President - Corporate Affairs and Human Resources of Ariad Pharmaceuticals, Inc. since November 2013, She has served as company's Senior Vice President, Corporate Affairs and Human Resources since November 2013, having served as company's Senior Vice President, Corporate Affairs since January 2012. Previously, she served as company's Vice President, Corporate Communications and Investor Relations since July 2008. Ms. Cantor held several positions of increasing responsibility at Genzyme Corporation from 2001 to 2008, most recently serving as Senior Director, Corporate Communications.

Daniel Bollag

Dr. Daniel M. Bollag, Ph.D. is Senior Vice President - Regulatory Affairs and Quality of Ariad Pharmaceuticals, Inc. since January 2009. He previously was Vice President, Regulatory Affairs for Genzyme Corporation, a biotechnology company, from 2006 to 2008.

Hugh Cole

Mr. Hugh M. Cole is Senior Vice President, Chief Business Officer of Ariad Pharmaceuticals, Inc. Mr. Cole is a seasoned pharmaceutical executive with more than 25 years of industry experience and a deep background in rare and orphan pharmaceutical markets. Prior to joining ARIAD, he spent seven years at Shire Pharmaceuticals, most recently as senior vice president, strategic planning and program management and as a global franchise head, and before that, as vice president, business development. Previously, he held senior positions in business and corporate development at Oscient Pharmaceuticals (formerly Genome Therapeutics) and at Millennium Pharmaceuticals and its affiliates. Mr. Cole led numerous successful acquisitions both at Shire and Oscient. Hugh started his career as an investment analyst at Fred Alger Management and then as a Principal at the Wilkerson Group, a consulting and advisory firm. He has an AB degree in chemistry from Harvard and an MBA degree from the Wharton School at the University of Pennsylvania, focused on healthcare management and finance.

Frank Haluska

Dr. Frank G. Haluska, M.D, Ph.D., is Senior Vice President - Clinical Research and Development and Chief Medical Officer of Ariad Pharmaceuticals, Inc., since January 2012. He has held the position of Vice President and Chief Medical Officer since June 2010. Previously, he served as Vice President, Clinical Affairs from May 2009 to June 2010, Vice President, Clinical Research from July 2008 to May 2009, and Senior Medical Director from October 2007 to July 2008. He received his M.D. degree and Ph.D. degree from the University of Pennsylvania School of Medicine and A.B. degree from Harvard University.

Timothy Clackson

Dr. Timothy P. Clackson, Ph.D., is President - Research and Development, Chief Scientific Officer of Ariad Pharmaceuticals, Inc. since June 2010. Previously, he served as Senior Vice President and Chief Scientific Officer from September 2003 to June 2010. Dr. Clackson received his B.A. degree in Biochemistry from the University of Oxford, and his Ph.D. degree in Biology from the University of Cambridge for research conducted at the MRC Laboratory of Molecular Biology that included the development of antibody phage display technology.

Wayne Wilson

Mr. Wayne R. Wilson is Lead Independent Director of Ariad Pharmaceuticals, Inc. since October 2008. He has over thirty years of business, financial, and accounting experience. He has been an independent business advisor since 2002. From 1995 to 2002, he served in various roles, including as President, Chief Operating Officer, and Chief Financial Officer, at PC Connection, Inc. From 1986 to 1995, Mr. Wilson was a partner in the assurance and advisory services practice of Deloitte & Touche LLP. Mr. Wilson has been a member of the Board since October 2008. He is chair of the Audit Committee and a member of the Nominating and Corporate Governance Committee and the Executive Committee. Mr. Wilson is also a member of the boards of directors of FairPoint Communications, Inc., a telecommunications company, Hologic, Inc., a medical diagnostics and device company focusing on women’s health, and Edgewater Technology, Inc., a technology management consulting firm. He previously served as a director of Cytyc Corporation, a medical diagnostics and device company. Mr. Wilson received an A.B. degree in political science from Duke University and an M.B.A. from the University of North Carolina at Chapel Hill.

Athanase Lavidas

Dr. Athanase Lavidas, Ph.D., is Director of Ariad Pharmaceuticals, Inc., since November 2008. He has been the Chairman and Chief Executive Officer of the Lavipharm Group, a pharmaceutical, cosmetics and consumer health-products company headquartered in Greece, since 1976. Dr. Lavidas is also Chairman of the Greece-U.S. Business Council and Chairman of SEV Business Council for International Activities, the international arm of the Hellenic Federation of Industries and Enterprises (SEV). Dr. Lavidas has been a member of our Board since September 2003 and served as our lead director from November 2008 until January 2014. He is chair of the Nominating and Corporate Governance Committee and a member of the Compensation Committee. Dr. Lavidas brings to the Board over thirty years of international pharmaceutical industry experience in strategic development and operational management. Dr. Lavidas has expertise in the research, development and commercialization of innovative pharmaceutical and cosmetic products, as well as global pharmaceutical and biotechnology collaborations. Dr. Lavidas received his B.S. and M.S. in chemistry from the University of Munich, his M.B.A. from the Institut Superieur de Marketing et de Management in Paris and his Ph.D. degree in pharmaceutical chemistry from the University of Athens.

Sarah Schlesinger

Dr. Sarah J. Schlesinger, M.D., has been appointed as Director of Ariad Pharmaceuticals, Inc., effective July 15, 2013. Dr. Schlesinger is a clinical investigator and immunologist at The Rockefeller University (“Rockefeller”) in New York City who has spent more than 20 years working in the field of cellular immunity, including as clinical director of the laboratory led by the late Ralph M. Steinman, M.D., 2011 Nobel Laureate in Physiology or Medicine. She is currently Senior Attending Physician and Associate Professor of Clinical Investigation at the Laboratory of Cellular Physiology and Immunology at Rockefeller. Prior to joining Rockefeller in 2003, Dr. Schlesinger was a scientist at the International AIDS Vaccine Initiative in New York City from 2002 to 2003. From 1996 to 2002, Dr. Schlesinger was a Research Physician/Pathologist at the Division of Retrovirology at Walter Reed Army Institute of Research, having previously served, from 1994 to 2002, as Staff Pathologist at the Armed Force Institute of Pathology in Washington, DC. Dr. Schlesinger trained in Surgery at the Albert Einstein College of Medicine and began her career in pathology at Georgetown University in Washington, DC, and hospitals in New York including Buffalo General, Hospital New York and the Manhattan Eye, Ear and Throat Hospital. Dr. Schlesinger leads clinical trials and also chairs the research education and training committee of the Center for Clinical and Translational Science at The Rockefeller University Hospital. She is co-director of Rockefeller’s Clinical Scholars program, the Certificate in Clinical and Translational Sciences program and is the vice-chair of the hospital’s Institutional Review Board. Widely published in her field, Dr. Schlesinger has been recognized with numerous awards for her research and teaching. Dr. Schlesinger received her bachelor’s degree from Wellesley College in Wellesley, MA, and her M.D. from Rush Medical College in Chicago.

Alexander Denner

Dr. Alexander J. Denner, Ph.D., has been appointed as Independent Director of ARIAD Pharmaceuticals, Inc., effective February 20, 2014. He founded Sarissa Capital, a registered investment advisor, in 2012. Sarissa Capital focuses on improving the strategies of companies to better provide shareholder value. From 2006 to November 2011, Dr. Denner served as a Senior Managing Director of Carl C. Icahn’s investment activities. Prior to that, he served as a portfolio manager at Viking Global Investors, a private investment fund, and Morgan Stanley Investment Management, a global asset management firm, for the Health Sciences Trust Fund and the Biotechnology Fund. Dr. Denner is presently a director of Biogen Idec Inc. and VIVUS, Inc. During the past five years, Dr. Denner had also served as a director of the following life sciences companies: Amylin Pharmaceuticals, Inc., Enzon Pharmaceuticals, Inc. and Mast Therapeutics, Inc. Prior to that time, he served as a director of ImClone Systems Incorporated, where he also served as Chairman of the Executive Committee. Dr. Denner received his S.B. degree from the Massachusetts Institute of Technology and his M.S., M.Phil. and Ph.D. degrees from Yale University.

Jay LaMarche

Mr. Jay R. LaMarche is an Independent Director of Ariad Pharmaceuticals, Inc. since January 1992. He is a retired financial executive who brings to company's Board over forty years of financial and senior operating experience. He has served us for over twenty years as a director and in executive leadership positions including Chief Financial Officer and Treasurer from January 1992 to November 2000. Mr. LaMarche was our Executive Vice President from March 1997 to November 2000 and Senior Vice President, Finance from January 1992 to February 1997. Prior to joining ARIAD, he was Chief Financial Officer and a director of ChemDesign Corporation, a fine chemicals manufacturer. Previously, Mr. LaMarche was an audit partner with Deloitte Haskins & Sells, a public accounting firm. Mr. LaMarche also served as an officer in the United States Navy. Mr. LaMarche has been a member of our Board since January 1992. He is a member of the Audit Committee and the Nominating and Corporate Governance Committee. Mr. LaMarche provides the Board with an extensive knowledge of our operations, as well as expertise in financial and accounting issues, particularly as they relate to the pharmaceutical and biotechnology industry. Mr. LaMarche’s management experience and financial background serve him well in providing guidance concerning our operations and business strategy. Mr. LaMarche received his B.B.A. degree in public accountancy from the University of Notre Dame.

Massimo Radaelli

Dr. Massimo Radaelli, Ph.D., is an Independent Director of Ariad Pharmaceuticals, Inc. since October 2008. He the President and Chief Executive Officer of Noventia Pharma, a specialty pharmaceutical company focused on orphan drugs for the treatment of rare diseases, in particular for the central nervous system and respiratory system. Prior to joining Noventia in May 2009, Dr. Radaelli was President and Chief Executive Officer of Dompé International SA, the international pharmaceutical company of the Dompé Group. He joined Dompé in 1996 as director of corporate business development. Dr. Radaelli is also Executive Chairman of Bioakos Pharma Laboratories, a specialty pharmaceuticals company concentrated in the fields of gynecology, dermatology, ear, nose and throat and pediatrics and a director of Arriani International, SA, the international subsidiary of Arriani Pharmaceuticals, a pharmaceutical company in southeastern Europe. Since January 2014, Dr. Radaelli has served as a director of NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company. He also serves as a director of Innotex Sa, a privately held specialty pharmaceuticals and cosmetics business, and IDRI, a non-profit organization focused on neglected diseases. Dr. Radaelli is a member of the Italian Society of Pharmacology and has been awarded the highest ranking honor of the Italian Republic by the President and Prime Minister of Italy for merit acquired in the fields of science and biopharma and for his commitment to patients with rare diseases and unmet medical needs. Dr. Radaelli has been a member of our Board since October 2008. Dr. Radaelli received a University Degree in pharmaceutical sciences and a Ph.D. in clinical pharmacology from the University of Milan and an Executive Master of Business from Bocconi University of Milan.

Norbert Riedel

Dr. Norbert G. Riedel, Ph.D., is Independent Director of Ariad Pharmaceuticals, Inc. He was Corporate Vice President and Chief Scientific Officer of Baxter International Inc., a diversified healthcare company from March 2001 until January 2013. From 1998 to 2001, Dr. Riedel served as President and General Manager of the recombinant therapeutic proteins business unit and Vice President of Research and Development at Baxter’s bioscience business. Prior to joining Baxter, from 1996 to 1998, he was head of worldwide biotechnology and worldwide core research functions at Hoechst-Marion Roussel, now Sanofi-Aventis, a global pharmaceutical company. Previously, he held a series of scientific management positions at Hoechst-Marion Roussel and Hoechst AG. Dr. Riedel has been a member of the Supervisory Board of MediGene AG, since 2003. He is a member of the Board of Directors of the Illinois Biotechnology Industry Organization and also serves on the Advisory Board of Northwestern University’s Kellogg School of Management Center for Biotechnology, and the McCormick School of Engineering. Most recently, he was appointed by Illinois Governor Pat Quinn to the newly formed Illinois Innovation Council. From 1999 to 2010, Dr. Riedel was a member of the board of directors of Oscient Pharmaceuticals Corporation & Genome Therapeutics Corporation. Dr. Riedel was a postdoctoral fellow at Harvard University from 1984 to 1987 and an Assistant Professor and Associate Professor of medicine and biochemistry at Boston University School of Medicine from 1987 to 1991, is an adjunct professor at Boston University School of Medicine, and an adjunct professor of Medicine at Northwestern University’s Feinberg School of Medicine and was a visiting professor at Massachusetts Institute of Technology in 1992. In 2009, Dr. Riedel was elected as a member of the Austrian Academy of Sciences. Dr. Riedel received his Diploma in biochemistry from the University of Frankfurt in 1981 and his Ph.D. in biochemistry from the University of Frankfurt in 1983.

Robert Whelan

Mr. Robert M. Whelan, Jr., is an Independent Director of Ariad Pharmaceuticals, Inc. He has nearly forty years of investment banking experience working predominantly with high technology and healthcare companies. He has been the President of Whelan & Company, LLC, providing business and financial consulting and strategic services to a broad range of companies, since 2001. From 2001 to 2005, Mr. Whelan served as Managing Director of Valuation Perspectives, Inc., a consulting firm. Prior to that, he held a number of senior-level positions at various investment banking and brokerage firms. Mr. Whelan was Vice Chairman of Prudential Volpe Technology Group, the technology investment banking and research division of Prudential Securities. Prior to Prudential Volpe, he was Chief Operating Officer, Managing Director, board member and Head of Investment Banking of Volpe Brown Whelan & Company, a private technology and healthcare investment banking, brokerage and asset management firm. Volpe Brown Whelan & Company was acquired by Prudential Securities in 1999. From 2008 to 2009, Mr. Whelan was a Fellow at the Harvard University Advanced Leadership Initiative, an innovative year-long program aimed at providing a rigorous educational curriculum for exceptional leaders who have reached the height of their professions and are seeking to contribute their skills to solve global social problems. Mr. Whelan currently serves as chairman of the board of directors of Aspen Technology, Inc., a publicly traded provider of software and services for the process industries based in Burlington, Massachusetts. Mr. Whelan received a B.A. in history from Dartmouth College and a M.B.A. from Stanford University Graduate School of Business.

Kendra Adams

Basic Compensation

Options Compensation

Name Options Value

Harvey Berger

774,046 1,638,873

Edward Fitzgerald

276,000 686,280

Martin Duvall

0 0

David Berstein

409,571 471,691

Maria Cantor

19,978 261,844

Daniel Bollag

0 0

Hugh Cole

0 0

Frank Haluska

10,500 139,182

Timothy Clackson

281,099 1,464,928

Wayne Wilson

0 0

Athanase Lavidas

0 0

Sarah Schlesinger

0 0

Alexander Denner

0 0

Jay LaMarche

286,357 1,107,673

Massimo Radaelli

0 0

Norbert Riedel

0 0

Robert Whelan

0 0

Kendra Adams

0 0
Search Stocks